Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
8 studies found for:    JUXTAFOVEAL TELANGIECTASIS
Show Display Options
Rank Status Study
1 Unknown  Effect of Avastin in Juxtafoveal Telangiectasias
Condition: Telangiectasis
Interventions: Drug: Bevacizumab;   Procedure: Intravitreal injection of Bevacizumab
2 Active, not recruiting The Role of Macular Pigment Carotenoids in the Pathogenesis and Treatment of Macular Telangiectasia Type 2 (MacTel)
Condition: Idiopathic Juxtafoveal Telangiectasia
Intervention: Drug: zeaxanthin
3 Completed Ciliary Neurotrophic Factor (CNTF) Safety Trial in Patients With Macular Telangiectasia (Mactel)
Condition: Idiopathic Juxtafoveal Telangiectasia
Intervention: Biological: NT-501 implant
4 Completed
Has Results
High-Dose Lucentis (Ranibizumab 2.0mg) for the Treatment of Nonproliferative Idiopathic Parafoveal Telangiectasia
Conditions: Retinal Diseases;   Telangiectasis
Intervention: Drug: ranibizumab 2.0mg
5 Completed Ranibizumab in Idiopathic Parafoveal Telangiectasia (RIPT) Trial
Condition: Telangiectasia
Intervention: Drug: Ranibizumab
6 Completed Injected Ranibizumab to Treat Macular Telangiectasia With New Blood Vessel Formation
Condition: Telangiectasia
Intervention: Drug: Ranibizumab
7 Completed Injected Ranibizumab to Treat Macular Telangiectasia Without New Blood Vessel Formation
Condition: Telangiectasia
Intervention: Drug: Ranibizumab
8 Unknown  MPOD in Macular Teleangiectasia Following Supplementation of Lutein and Zeaxanthin
Conditions: Macular Teleangiectasia;   Macular Pigment
Intervention:

Study has passed its completion date and status has not been verified in more than two years.